DBV Technologies S.A. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by DBV Technologies S.A. on April 30, 2026. The filing discloses the approval of the DBV Technologies 2026 Performance Share Unit Plan and the subsequent grant of Performance Share Units (PSUs) to Daniel Tassé, the Company's Chief Executive Officer.
Key Financial Metrics
The filing does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on executive compensation arrangements.
Material Changes and Executive Compensation
On April 30, 2026, the Board of Directors approved the grant of 1,740,000 PSUs to CEO Daniel Tassé. The grant date is May 5, 2026. The award is structured as follows:
- Total Grant: 1,740,000 PSUs.
- Performance Conditions: Vesting is split 50/50 based on FDA acceptance for review of Biologics License Applications (BLA) for Viaskin Peanut in two age groups:
- 870,000 PSUs for FDA acceptance for patients aged 4-7 years.
- 870,000 PSUs for FDA acceptance for patients aged 1-3 years.
- Single BLA Provision: If a single BLA covers both age groups, all PSUs become eligible to vest.
- Vesting Deadline: Performance conditions must be met by July 1, 2028, or the PSUs are forfeited.
- Continued Employment: Vesting requires the CEO to remain employed continuously through the vesting date, with exceptions for death, disability, qualifying retirement, or termination without cause/for good reason.
- Delivery Schedule: Vested shares are delivered in four 25% installments on July 1, 2028; January 1, 2029; July 1, 2029; and January 1, 2030.
- Change in Control: All performance conditions are deemed achieved upon a Change in Control, though the continued employment condition and delivery schedule remain in effect.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or general outlook commentary. The primary risk highlighted is the forfeiture of the entire award if the FDA does not accept the relevant BLAs for review by July 1, 2028. Additionally, the award is contingent on the CEO's continued employment.
Key Facts for Investor Verification
- Verify the status of the Viaskin Peanut BLA submissions for the 4-7 and 1-3 age groups to assess the likelihood of PSU vesting.
- Confirm the CEO's continued employment status through the July 1, 2028 vesting date.
- Review the full text of the 2026 Performance Share Unit Plan (Exhibit 10.1) for specific definitions of "Cause," "Good Reason," and "Qualifying Retirement."
- Monitor for any future filings regarding the delivery of shares or potential cash substitutions if the CEO is not a French tax resident at the time of delivery.